天康生物(002100.SZ):控股股東減持100萬張天康轉債
格隆匯10月21日丨天康生物(002100.SZ)公佈,經中國證監會“證監許可[2017]2201號”文核准,公司於2017年12月22日公開發行了1000萬張可轉換公司債券(“天康轉債”),每張面值100元,發行總額10億元。其中,公司控股股東兵團國資公司配售天康轉債294.7184萬張,佔該次發行總量的29.47%。
2019年10月21日,公司接到控股股東兵團國資公司的告知函,自2019年8月15日至2019年10月21日期間,兵團國資公司通過深圳證券交易所交易系統減持天康轉債100萬張,佔發行總量的10.00%;此次減持後,兵團國資公司仍持有天康轉債194.7184萬張,佔發行總量的19.47%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.